FUJIFILM Pharmaceuticals USA
  • Home
  • Investigational Drug Development
  • Contract Services
    • LNPs and Liposomes
    • Nano-dispersion Technologies
  • Resources
    • Drug Delivery Formulation
    • Peer-Reviewed Publications and Conference Presentation
    • Oncology
    • Alzheimer’s Disease
  • News
  • About Us
  • Contact Us
Select Page

Fujifilm to establish its first Bio-CDMO site in Japan

Accelerating business growth of the life sciences field and contributing to the strengthening of domestic vaccine production in Japan

TOKYO, October 6, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces that it will establish the company’s first Japanese Bio-CDMO site in Toyama City, Toyama Prefecture. The new site will be invested by FUJIFILM Toyama Chemical and will be operational in FY2026.

The Japanese Government is currently promoting the strengthening of domestic vaccine production to prepare against future pandemics. As part of this effort, the Japanese Government supports projects such as establishing sites with dual-use facilities capable of producing biopharmaceuticals to meet customer needs during normal times and switching to vaccine production during a pandemic. Fujifilm’s investment has been selected for the project of “Developing biopharmaceutical manufacturing sites to strengthen vaccine production” promoted by the Ministry of Economy, Trade and Industry in Japan*1.

Fujifilm currently operates its own Bio-CDMO business globally, as well as drug discovery, development and manufacturing support, and offering culture media, cells and research reagents through a company-wide strategy led Fujifilm’s Life Sciences Strategy Headquarters. By leveraging Fujifilm’s global manufacturing sites and sales networks, the company has been expanding its business in the life sciences field mainly in Europe and the United States.

In order to expand business in the fast-growing Asian market, Fujifilm will establish a Bio-CDMO site equipped with dual-use facilities in Japan, operated by FUJIFILM Toyama Chemical in close collaboration with other Fujifilm Life Sciences entities. It will apply advanced biotechnologies and know-how nurtured through Fujifilm’s global business, which enables offering high-quality CDMO services. When an outbreak of infectious disease evolves into a pandemic, the site will strongly support pharmaceutical companies for development and delivery of domestic vaccines.

“With this strategic investment, Fujifilm will strongly support customers in the biopharmaceutical industry and accelerate business growth of the life sciences field”, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. “We hope the new site will play an important role in the Japanese Government’s initiative to strengthen vaccine production, thereby contributing to the health and well-being in Japan and other Asian countries.”

 

Overview of the new site


1.Features


  • The manufacturing site of FUJIFILM Toyama Chemical will be equipped with the facilities capable of development of manufacturing process of biopharmaceuticals. In addition, new buildings for investigational drug manufacturing and commercial production of biopharmaceuticals will be constructed in the site.
  • The site will feature dual-use facilities capable of manufacturing biopharmaceuticals such as antibody drugs and antibody drug conjugates (ADC*2) and switching to manufacturing mRNA vaccines and genetically-engineered protein vaccines during pandemic. The site will be able to provide end-to-end services from drug substance production, through to fill-finish and final packing.
  • The site will be applied with the cutting-edge biotechnologies including cell culture and purification technologies and genetic engineering technology of FUJIFILM Diosynth Biotechnologies, a group company with over 30 years of experience as a Bio-CDMO offering services for broad range of biopharmaceuticals. These technologies will facilitate high-efficiency production, enabling fast and stable supply of high-quality biopharmaceuticals.
  • Fujifilm will offer comprehensive Bio-CDMO services to clients, through close collaboration between FUJIFILM Toyama Chemical, FUJIFILM Diosynth Biotechnologies and FUJIFILM Wako Pure Chemical.

2.Operational timing



in FY2026 ending March 2027


*1 The grant amount will be determined in FY2023 ending March 2024.
*2 ADC is a class of biopharmaceutical agent that combines a drug such as an anti-cancer agent with antibodies. The antibodies in ADC bind with antigens present on the surface of cancer cells to enable targeted delivery of a drug. Due to this mechanism, ADC is expected to provide a greater treatment effect with less side effects.

Contact

Media Contact

FUJIFILM Holdings Corporation
Corporate Communications Division,
Public Relations Group
TEL +81-3-6271-2000

 

* Please note that the contents including the product availability, specification, prices and contacts in this website are current as of the date of the press announcement and may be subject to change without prior notice.

###

PRIVACY POLICY      TERMS OF USE

TRUSTe
  • Follow
© 2022 FUJIFILM Pharmaceuticals U.S.A., Inc.
Cookies are important to the proper functioning of a site. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.
By continuing to use this site you are giving us your consent to do this. For more information you can read our Privacy Policy. Accept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT

Tumor targeting by liposomes

Liposomes provide a delivery system that carries the required amount of a drug to the specific area of the body. Because of that, one potential application for liposomes is anti-cancer formulations. Studies have suggested that liposomes are delivered to tumors through the enhanced permeability and retention (EPR) effect1. As a passive targeting mechanism, EPR effect allows the accumulation of drugs within the tumor tissue thanks to immature, highly permeable vasculature and ineffective lymphatic system that allow efficient extravasation of such macromolecules.

1 Yingchoncharoen P., Kalinowski D.S., Richardson D.R. 2016. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev. 68(3):701-87.

Promising vehicle for nucleic acids

Nucleic acids (mRNA, siRNA, DNA aptamers, etc.) are the new frontiers of drug discovery. However, the industry has faced technological challenges in commercializing nucleic acid medicines due to their poor pharmacological stability. Lipid nanoparticle has been studied for a decade as a potential solution to this problem, which recently is coming to fruition in some clinical applications, such as mRNA-based COVID-19 vaccines.